Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 336

The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.

TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM

Open access
Hung, Alice L., Maxwell, Russell, Theodros, Debebe, Belcaid, Zineb, Mathios, Dimitrios, Luksik, Andrew S., Kim, Eileen, Wu, Adela, Xia, Yuanxuan, Garzon-Muvdi, Tomas, Jackson, Christopher, Ye, Xiaobu, Tyler, Betty, Selby, Mark, Korman, Alan, Barnhart, Bryan, Park, Su-Myeong, Youn, Je-In, Chowdhury, Tamrin, Park, Chul-Kee, Brem, Henry, Pardoll, Drew M., Lim, Michael·2018·OncoImmunology
DOI 10.1080/2162402x.2018.1466769
Open this paper in CoChat — free account

Abstract

The use of inhibitory checkpoint blockade in the management of glioblastoma has been studied in both preclinical and clinical settings. TIGIT is a novel checkpoint inhibitor recently discovered to play a role in cancer immunity. In this study, we sought to determine the effect of anti-PD-1 and anti-TIGIT combination therapy on survival in a murine glioblastoma (GBM) model, and to elucidate the underlying immune mechanisms. Using mice with intracranial GL261-luc+ tumors, we found that TIGIT expression was upregulated on CD8+ and regulatory T cells (Tregs) in the brain compared to draining cervical lymph nodes (CLN) and spleen. We then demonstrated that treatment using anti-PD-1 and anti-TIGIT dual therapy significantly improved survival compared to control and monotherapy groups. The therapeutic effect was correlated with both increased effector T cell function and downregulation of suppressive Tregs and tumor-infiltrating dendritic cells (TIDCs). Clinically, TIGIT expression on tumor-infiltrating lymphocytes was shown to be elevated in patient GBM samples, suggesting that the TIGIT pathway may be a valuable therapeutic target. Expression of the TIGIT ligand, PVR, further portended a poor survival outcome in patients with low-grade glioma. We conclude that anti-TIGIT is an effective treatment strategy against murine GBM when used in combination with anti-PD-1, improving overall survival via modifications of both the T cell and myeloid compartments. Given evidence of PVR expression on human GBM cells, TIGIT presents as a promising immune therapeutic target in the management of these patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/2162402x.2018.1466769

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 63 references

Cited by

See all 336

Metadata

Authors
Hung, A. L., Maxwell, R., Theodros, D., Belcaid, Z., Mathios, D., Luksik, A. S., Kim, E., Wu, A., Xia, Y., Garzon-Muvdi, T., Jackson, C., Ye, X., Tyler, B., Selby, M., Korman, A., Barnhart, B., Park, S.-M., Youn, J.-I., Chowdhury, T., Park, C.-K., Brem, H., Pardoll, D. M., & Lim, M.
Venue
OncoImmunology
Publisher
Informa UK Limited
Published
2018-05-24
Volume
7
Issue
8
Pages
e1466769
ISSN
  • 2162-4011 (ISSN-L)
  • 2162-402X
DOI
10.1080/2162402x.2018.1466769
OpenAlex
W2803225762
Cited by
336
References
63
FWCI
12.22
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM. https://app.cochat.ai/papers/10.1080/2162402x.2018.1466769
The paper
Hung, A. L., Maxwell, R., Theodros, D., Belcaid, Z., Mathios, D., Luksik, A. S., Kim, E., Wu, A., Xia, Y., Garzon-Muvdi, T., Jackson, C., Ye, X., Tyler, B., Selby, M., Korman, A., Barnhart, B., Park, S.-M., Youn, J.-I., Chowdhury, T., . . . Lim, M. (2018). TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM. OncoImmunology. https://doi.org/10.1080/2162402x.2018.1466769

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.